München (ots) - Wenn es um den Einkauf von Luxuswaren wie Uhren und Schmuck geht, setzen Schweizer ...
Scientific Recognition for Solianis based on Successful Tests
Zurich, Swizerland (ots) - Recently, Solianis successfully finalized a series of tests during which patients with diabetes have worn its multisensor device for non-invasive glucose monitoring at home and at work in the office. The results of these real-life tests as well as earlier tests in a more controlled environment have encouraged Solianis to set up the final device and prepare the market introduction for 2010.
The results of this groundbreaking study will be presented this year by Dr. Andreas Caduff, Solianis Chief Technology Officer, to the world's leading diabetes experts at the most important international conferences such as the "2nd International ATTD Conference on Advanced Technologies & Treatments for Diabetes (ATTD)" in Athens, the meetings of the American Diabetes Association" and the "European Association for the Study of Diabetes".
"Solianis has reached another important milestone by successfully closing these tests and will now present the status of its technology to specialized audiences. This means that Solianis has earned scientific recognition for almost four years of hard work" says Mario Stark, CEO of Solianis. Solianis Monitoring AG is a medical devices company developing a non-invasive Continuous Glucose Monitor (CGM) for self-monitoring patients with diabetes. Its technology is based on a unique and proprietary multisensor technology for monitoring physiological parameters. Solianis' non-invasive device delivers comparable results to the minimally invasive devices currently approved by the FDA.
Solianis was incorporated in May 2005, and is funded by private investors and the Pioneer Fund of the Cantonal Bank of Zurich. The company plans to introduce its first-generation device for insulin-dependent patients with diabetes by 2010 in Europe, after CE approval. Later product generations will target all patients with diabetes and impaired glucose tolerance.
ots Originaltext: Solianis Monitoring AG